ArticleActa pharmaceutica Sinica. B2022
Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment.
Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Nanogels as target drug delivery systems in cancer therapy: A review of the last decade.Frontiers in pharmacology · 2022Pooled it
- Polymeric Materials in Cancer Immunotherapy: Advances, Challenges, and Future Directions.Polymer science & technology (Washington, D.C.) · 2026Review
- Natural Product-Based Nanomedicine in the Treatment of Breast Cancer.Pharmaceutics · 2026Review
- Immune-Evasive Biomimetic Gold-Carbon Nanoplatform for Dual-Modal Theranostics of Hepatocellular Carcinoma.Small methods · 2026Article
- Targeting cytokine/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Review
- Nanoparticles coated with osteoblast-like cell membranes as curcumin delivery vehicles for targeted postmenopausal osteoporosis therapy.Materials today. Bio · 2026Article
- Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy.Nanomaterials (Basel, Switzerland) · 2026Review
- Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy.Frontiers in immunology · 2026Review
- Theragenerative Nanomaterials: Integrating Therapy, Regeneration, and Diagnosis-Navigating the Shared Pathways Between Tissue Repair and Malignancy.International journal of nanomedicine · 2026Review
- Cell membrane biomimetic nanoplatforms: a new strategy for immune escape and precision targeted therapy.Materials today. Bio · 2025Review
- Lenalidomide promotes melarsoprol-activated cGAS-STING-mediated immunotherapy for hepatocellular carcinomaFundamental research · 2025Article
- Aromatic Anion Carrier via Self-Assembly with Imidazolium-Fused Aromatic Amphiphiles.Precision chemistry · 2025Article
- Advancements and Prospects of pH-Responsive Hydrogels in Biomedicine.Gels (Basel, Switzerland) · 2025Review
- Advancements in research on the precise eradication of cancer cells through nanophotocatalytic technology.Frontiers in oncology · 2025Review
- Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer.Materials today. Bio · 2024Review
- Cell Membrane-Coated Biomimetic Nanoparticles in Cancer Treatment.Pharmaceutics · 2024Review
- Controlled delivery of 5-fluorouracil from monodisperse chitosan microspheres prepared by emulsion crosslinking.RSC advances · 2024Article
- Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy.Journal of hematology & oncology · 2024Review
- Cancer Immunotherapy Using Bioengineered Micro/Nano Structured Hydrogels.Advanced healthcare materials · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the development of chemo-immunotherapy, many efforts have been focusing on designing suitable carriers to realize the co-delivery of chemotherapeutic and immunotherapeutic with different physicochemical properties and mechanisms of action. Besides, rapid drug release at the tumor site with minimal drug degradation is also essential to facilitate the antitumor effect in a short time. Here, we reported a cancer cell membrane-coated pH-responsive nanogel (NG@M) to co-deliver chemotherapeutic paclitaxel (PTX) and immunotherapeutic agent interleukin-2 (IL-2) under mild conditions for combinational treatment of triple-negative breast cancer. In the designed nanogels, the synthetic copolymer PDEA-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.